Patents Examined by Fozia Hamud
  • IL-17 receptor like molecules and uses thereof
    Patent number: 7094566
    Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 22, 2006
    Assignee: Amgen Inc.,
    Inventors: Eugene Medlock, Richard Yeh, Scott M. Silbiger, Gary S. Elliott, Hung Q. Nguyen, Shuqian Jing
  • Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
    Patent number: 7078494
    Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: July 18, 2006
    Assignee: Genetics Institute, LLC
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Compositions and methods of use for a bombesin peptide
    Patent number: 7078413
    Abstract: The present invention discloses a seven amino acid peptide (7AA) of bombesin. Methods for reducing the impairment respiratory tract mucosal immunity, reducing the rate of infection of the respiratory tract by pathogenic microorganisms and reducing the atrophy or dysfunction of the GALT comprising administering an effective amount of 7AA are also provided.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: July 18, 2006
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Kenneth A. Kudsk
  • Secreted and transmembrane polypeptides nucleic acid encoding
    Patent number: 7074592
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: July 11, 2006
    Assignee: Genetech, Inc.
    Inventors: Avi Ashkenazi, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Jenni P. Mather, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • System for screening fatty acid transport inhibitors, methods of use and modulators identified thereby
    Patent number: 7070944
    Abstract: Methods for identifying modulators of fatty acid transport and/or uptake, comprising contacting, under conditions favorable for fatty acid uptake, a putative modulator, e.g., an inhibitor with a system comprising genetic material encoding a fatty acid transport mediator (“TTM”), particularly FAA1, FAA2, FAA3, FAA4, FAT1, fadL, fadD, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, or fatty acid transport mediator proteins (“TTMps”), e.g., Faa1p, Faa2p, Faa3p, Faa4p, Fat1p, FadL, fatty acyl CoA synthetase, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, and determining the effect of the putative modulator. The test system may be a cell such as Saccharomyces cerevisiae, E. coli, H. sapiens, etc. or an in vitro system.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: July 4, 2006
    Assignee: CLF Medical Technology Acceleration Program, Inc.
    Inventors: Paul Black, Concetta DiRusso
  • Antibody against the human toll- like receptor 2 (tlr2) and uses thereof
    Patent number: 7071310
    Abstract: The present invention relates to an antibody capable of binding to human TLR2 and which (i) binds only to CD14+ cells in a normal human mononuclear cell population, and not to CD14? cells; (ii) does not inhibit LPS-induced activation of normal human mononuclear cells, and to the uses thereof, for example in the treatment of bacterial infections which are mediated via the TLR2 receptor, especially bacterial sepsis. In a particular embodiment of this aspects, a utility in the treatment of Listeria infections is proposed. The antibodies also have a utility as a general research tool, for example in screening for TLR2 expression, and in the study of TLR2 function. A further aspect of the invention provides use of an agent capable of inhibiting TLR2 activation in the preparation of a composition for the treatment of Listeria infections.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: July 4, 2006
    Assignee: Leiv Eiriksson Nyskaping AS
    Inventors: Terje Espevik, Anders Sundan
  • Stimulating neutrophil function to treat inflammatory bowel disease
    Patent number: 7060262
    Abstract: Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: June 13, 2006
    Assignee: The Washington University
    Inventors: Brian K. Dieckgraefe, Joshua Korzenik
  • Antibodies which specifically bind to TNF-R
    Patent number: 7057022
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: June 6, 2006
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Purified human erythropoietin receptor protein fragment and antibodies derived therefrom
    Patent number: 7053184
    Abstract: A E. coli recombinant plasmid expressing a fusion protein having the human erythropoietin receptor extracellular domain is disclosed. A purified fusion protein produced from such a vector is also disclosed, the fusion protein having a cleavage site suitable for separating the erythropoietin receptor extracellular domain from the remainder of the fusion protein. Antibodies having specific binding affinity for a purified extracellular domain polypeptide are also disclosed. The purified human erythropoietin receptor fragment polypeptide binds erythropoietin. The articles, compositions and methods of the invention are useful for studying ligand binding to erythropoietin receptor and for quantitating the amounts of erythropoietin receptor, as well as for understanding receptor structure and signal transduction.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: May 30, 2006
    Inventor: Jong Y. Lee
  • Human histamine receptor of the H3 subtype
    Patent number: 7049401
    Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: May 23, 2006
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati
  • Soluble Zcytor11 cytokine receptors
    Patent number: 7045498
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: May 16, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Stavros Topouzis
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7041805
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Sherman Fong, Wei-Qiang Gao, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, P. Mickey Williams, William I. Wood
  • Antibodies to PRO1387 polypeptides
    Patent number: 7041804
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising these nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Colin K. Watanabe, William I. Wood
  • Nucleic acid molecules encoding SIGIRR polypeptides
    Patent number: 7037675
    Abstract: The invention is directed to purified and isolated SIGIRR polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: May 2, 2006
    Assignee: Immunex Corporation
    Inventor: John Ernest Sims
  • Isolated cytokine receptor LICR-2
    Patent number: 7033787
    Abstract: The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: April 25, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean-Christophe Renauld, Helmut Fickenscher, Laure Dumoutier, Simon Hör
  • Polynucleotide encoding IL-1 zeta polypeptide
    Patent number: 7033783
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: April 25, 2006
    Assignee: Immunex Corp.
    Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
  • Nucleic acids to PRO1387 polypeptides
    Patent number: 7029873
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: April 18, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Colin K. Watanabe, William I. Wood
  • Megakaryocyte stimulating factors
    Patent number: 7030223
    Abstract: Novel polypeptides of human megakaryocyte stimulating factors (MSFs). Pharmaceutical compositions containing same, and methods for their preparation and use are provided.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: April 18, 2006
    Assignee: Genetics Institute LLC
    Inventors: Katherine Turner, Steven C. Clark, Kenneth Jacobs, Rodney M. Hewick, Thomas G. Gesner
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7026449
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: April 11, 2006
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Sherman Fong, Wei-Qiang Gao, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, P. Mickey Williams, William I. Wood
  • PRO 1387 polypeptides
    Patent number: 7019116
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: March 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Colin K. Watanabe, William I. Wood